Literature DB >> 8500741

Ablation of persistent hepatitis B by bone marrow transplantation from a hepatitis B-immune donor.

Y Ilan1, A Nagler, R Adler, R Tur-Kaspa, S Slavin, D Shouval.   

Abstract

Chronic hepatitis B virus (HBV) infection is still a major cause of liver disease for which no definite therapy is available. We describe here a hepatitis B surface antigen (HBsAg) carrier patient with active viral replication (HBV DNA positive) who was treated for leukemia by bone marrow transplantation (BMT) from an HBV immune donor. Following BMT from the antibody to hepatitis B core antigen (anti-HBc) positive/anti-HBs positive bone marrow donor, immune reconstitution of the recipient's bone marrow resulted in clearance of the circulating HBsAg, as well as HBV DNA. The patient acquired immunity against HBV, which lasted for more than 8 months posttransplantation. Therefore, this report provides evidence that adoptive transfer of specific immunity against HBV through allogeneic BMT may lead to clearance of persistent HBV infection. Furthermore, the data support the hypothesis that the HBsAg carrier state is most probably the result of an inefficient immune response against HBV, implying that clearance of HBV may be facilitated by adoptive cellular immunotherapy.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8500741     DOI: 10.1016/0016-5085(93)90664-x

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  21 in total

Review 1.  The woodchuck as an animal model for pathogenesis and therapy of chronic hepatitis B virus infection.

Authors:  Stephan Menne; Paul J Cote
Journal:  World J Gastroenterol       Date:  2007-01-07       Impact factor: 5.742

Review 2.  Circumventing failed antiviral immunity in chronic hepatitis B virus infection: triggering virus-specific or innate-like T cell response?

Authors:  Sarene Koh; Antonio Bertoletti
Journal:  Med Microbiol Immunol       Date:  2014-12-16       Impact factor: 3.402

Review 3.  Living in the liver: hepatic infections.

Authors:  Ulrike Protzer; Mala K Maini; Percy A Knolle
Journal:  Nat Rev Immunol       Date:  2012-02-24       Impact factor: 53.106

4.  HBV life cycle and novel drug targets.

Authors:  Daniel Grimm; Robert Thimme; Hubert E Blum
Journal:  Hepatol Int       Date:  2011-03-08       Impact factor: 6.047

Review 5.  Management of chronic hepatitis B before and after liver transplantation.

Authors:  James Fung
Journal:  World J Hepatol       Date:  2015-06-08

6.  Development of immunity against hepatitis B virus after donor lymphocyte infusion in a peripheral blood stem cell transplantation recipient with chronic hepatitis B.

Authors:  L-T Chiang; M Yao; B-S Ko; C-H Chen
Journal:  Infection       Date:  2011-05-05       Impact factor: 3.553

7.  Immune therapy for hepatocellular carcinoma.

Authors:  Yaron Ilan
Journal:  Hepatol Int       Date:  2013-12-20       Impact factor: 6.047

Review 8.  Specific CD8(+) T cell response immunotherapy for hepatocellular carcinoma and viral hepatitis.

Authors:  Elia Moreno-Cubero; Juan-Ramón Larrubia
Journal:  World J Gastroenterol       Date:  2016-07-28       Impact factor: 5.742

9.  Development of antibodies to hepatitis B virus surface antigen in bone marrow transplant recipient following treatment with peripheral blood lymphocytes from immunized donors.

Authors:  Y Ilan; A Nagler; D Shouval; A Ackerstein; R Or; J Kapelushnik; R Adler; S Slavin
Journal:  Clin Exp Immunol       Date:  1994-08       Impact factor: 4.330

Review 10.  Management of chronic hepatitis B infection: current treatment guidelines, challenges, and new developments.

Authors:  Ceen-Ming Tang; Tung On Yau; Jun Yu
Journal:  World J Gastroenterol       Date:  2014-05-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.